Biological
Tetanus Toxoid clinical trials
- studies test it
- 9
- open now
- 0
- in phase 3
- 1
- first study started
- 2001
How studies write it
Studies that test it under each name
Name
Studies by the year they started
9 studies that test it; most in 2001 (1)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 2
- Phase 3
- 1
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 6
Gary Archer Ph.D. (2) · Beijing Minhai Biotechnology Co., Ltd (1) · Sinovac Life Sciences Co., Ltd. (1) · Sanofi Pasteur, a Sanofi Company (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Jawaharlal Institute of Postgraduate Medical Education & Research (1) · Masonic Cancer Center, University of Minnesota (1) · Herbert Irving Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
SNA02-48 (1) · Therapeutic Autologous Lymphocytes (1) · Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (1) · Pertussis Vaccine (1) · Rotavirus Vaccines (1) · Pneumococcal Vaccines (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Keyhole limpet hemocyanin (1)
Studies
Open first, then newest update. How each study uses Tetanus Toxoid is read from its arms, and is right about nine times in ten.
Testing it · 9
- Phase I/III Clinical Trial of Adsorbed Tetanus VaccineCompletedPhase 3Beijing Minhai Biotechnology Co., LtdNCT07740733Written as Tetanus Toxoid (Adsorbed)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult ParticipantsCompletedPhase 1/2Sinovac Life Sciences Co., Ltd.NCT06939777Written as Tetanus Toxoid
- Routine Antibiotic vs. Directed Antibiotic Treatment in Snake BiteTerminatedPhase 4Jawaharlal Institute of Postgraduate Medical Education & ResearchNCT02570347Written as Tetanus toxoid
- Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedPhase 1Gary Archer Ph.D.NCT00639639Written as tetanus toxoid
- Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous DoseCompletedPhase 4Sanofi Pasteur, a Sanofi CompanyNCT01439165Written as Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine
- Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent MedulloblastomaCompletedPhase 1Gary Archer Ph.D.NCT03615404Written as Td (tetanus toxoid)
- CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell TransplantTerminatedPhase 1Masonic Cancer Center, University of MinnesotaNCT00369291Written as tetanus toxoid
- The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune ResponsesCompletedNot applicableAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT02538211Written as Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
- Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal CancerStatus unknownPhase 2Herbert Irving Comprehensive Cancer CenterNCT00027833Written as tetanus toxoid
Given in every arm · 4 — Tetanus Toxoid is usual care beside what is tested
- Analyzing Childhood Recall Antigens in Patients With Pancreatic CancerTerminatedPhase 2Albert Einstein College of MedicineNCT03848182Written as TT vaccine booster
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy AdultsCompletedPhase 1/2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT06302374Written as Tetanus Toxoid
- A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsTerminatedPhase 1/2Bristol-Myers SquibbNCT03251924Written as Tetanus Vaccine
- An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedPhase 1/2Bristol-Myers SquibbNCT02737475Written as Tetanus vaccine